Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry Events
FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and American Association of Immunologists’ (AAI) IMMUNOLOGY2025. Designed to streamline workflows, accelerate discoveries, and enhance efficiency, FSP technology will be the focus of a variety of demonstrations, educational workshops and tutorials at these prominent industry gatherings.
Flow cytometry plays a crucial role in both research and clinical studies, and Cytek is at the forefront of making this powerful technology more accessible and scalable. By empowering scientists to accelerate discovery and deliver deeper, more actionable insights, Cytek is unlocking new opportunities across high-growth areas like immunology, oncology, and cell therapy. As a pioneer in spectral flow cytometry, Cytek’s differentiated platform is not only advancing scientific understanding but also expanding its footprint in a rapidly evolving market.
IMMUNOLOGY2025 May 3, 2025 – May 7, 2025 Honolulu, Hawaii Booth: 801 The American Association of Immunologists’ (AAI) annual meeting has become the leading annual all-immunology event worldwide, bringing together a global community of immunologists. At this year’s conference, Cytek will showcase its complete cell analysis solutions that enable scientists to advance their research, gain deeper insights, and fast-track discovery. The company’s comprehensive, integrated suite of solutions includes the Cytek portfolio of instruments, reagents, Cytek® Cloud, software and services.
Also at IMMUNOLOGY2025, Eleanor Kincaid, Ph.D., field applications manager, eastern U.S. for Cytek Biosciences, will host an exhibitor workshop. Titled “A Robust Approach for In-Depth Characterization of Mouse Immune Responses Using the Cytek 24-Color Mouse Immunoprofiling Panel,” this workshop will take place on Sunday, May 4, 2025, from 1:15 p.m. – 2:00 p.m.
CYTO 2025 May 31, 2025 – June 4, 2025 Denver, Colorado Booth: 401 CYTO 2025, the 38th annual Congress of the International Society for the Advancement of Cytometry, is a leading global conference that brings together the many facets of cytometry science and engineering in an inclusive and dynamic setting. At CYTO, Cytek, a Platinum sponsor of the conference, will showcase its technology, designed to accelerate scientific discovery. Built with the scientist in mind, Cytek’s solutions continually evolve and expand to enhance the research experience.
“We’re thrilled to be part of CYTO 2025, the industry’s premier event, where the brightest minds in cytometry come together to shape the future of the field,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “As a leader in spectral flow cytometry, Cytek is committed to making this powerful technology more accessible than ever – enabling scientists to push the boundaries of discovery. By delivering innovative, flexible solutions, we’re equipping researchers with the tools and knowledge they need to accelerate breakthroughs and drive the next era of scientific advancement.”
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™ and Cytek Aurora™ CS systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek’s business strategies, product plans and expectations, market opportunities and expansion. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could materially affect future results include, but are not limited to, global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Annual Report on Form 10-K filed on February 28, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release.
Media Contact: Stephanie Olsen Lages & Associates (949) 453-8080 stephanie@lages.com
Investor Contact: Paul Goodson Head of Investor Relations Cytek Biosciences pgoodson@cytekbio.com
